Alexion's top brass has hit the exits amid an investigation into sales practices, and Ophthotech's future is in jeopardy following a high-profile phase 3 failure.
News & Analysis: Ophthotech
Shares collapse after the company reports disappointing results from two phase 3 clinical trials.
Shares drop over new concerns regarding the company's lead compound.
Shares fall in response to bad news from a competing drug's clinical trial.
It's been a rough year for the clinical-stage biotech. Here's a look back at the key events that have contributed to the stock's decline.
Investors are growing optimistic about upcoming phase 3 trial results for the company's lead drug candidate.
Investors may have been reading too much into a couple of C-suiters' tax-season moves.
The launch of trials in dry age-related macular degeneration failed to spark shares last month.